AzTrials
AzTrials

TracheobronchomalaciaNCT04217603

Effect of CPAP on 6-Minute Walk Test Outcomes in Patients With ECAC

A study testing Continuous positive airway pressure (CPAP) device in people with Tracheobronchomalacia and Excessive Dynamic Airway Collapse, run by Beth Israel Deaconess Medical Center at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this protocol is to perform a prospective, randomized, double-blinded, pacebo-controlled clinical trial to determine the influence of a non-invasive positive pressure ventilation device on exercise capacity and symptoms in adult patients with ECAC. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Continuous positive airway pressure (CPAP) device
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
32 participants
Where
1 siteUnited States
Study dates
1 Mar 2023to 29 Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient with a diagnosis of ECAC either via bronchoscopy or CT Scan
  • Age > 18 years
  • Patients that will undergo a diagnostic or therapeutic bronchoscopy as part of their standard of care
  • Patients with a baseline 6 MWT
  • Patients that have never used CPAP devices in the past

Who cannot join

  • Patients with poorly-controlled respiratory comorbidities (asthma, COPD, obstructed sleep apnea, GERD, relapsing polychondritis)
  • No evidence for acute respiratory tract infection, or respiratory tract infection within the prior 3 weeks
  • Resting bradycardia (<50 beats/min), frequent multifocal PVCs, complex ventricular arrhythmia, sustained SVT
  • Dysrhythmia that might pose a risk during exercise or training
  • Any disease or condition that interferes with completion of initial or follow-up assessments
  • Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g., severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea.
Show all 9Show fewer
  • Subject has an inability to walk >140m (150 yd) in 6 minutes
  • Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.
  • Subject has a known sensitivity to drugs required to perform bronchoscopy.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

    Adnan Majid, MD FCCP, 617 6328252, amajid@bidmc.harvard.edu

    Adnan Majid, MD FCCP

    Recruiting

Other trials in United States

About this study

Official title: Effect of Continuous Positive Airway Pressure (CPAP) on 6-Minute Walk Test Outcomes in Patients With Excessive Central Airway Collapse (ECAC)

The purpose of this protocol is to perform a prospective, randomized, double-blinded, pacebo-controlled clinical trial to determine the influence of a non-invasive positive pressure ventilation device on exercise capacity and symptoms in adult patients with ECAC. Primary outcome will include the total distance traversed by the study subject during a standard 6-minute walk test, and secondary outcomes will include peak flow measurement and symptom reporting before and after the exercise testing. The study will focus on the use of continuous positive airway pressure (CPAP) device. CPAP is FDA-approved for the treatment of various medical conditions, including obstructive sleep apnea and heart failure, but is not FDA-approved for the treatment of ECAC. The study will enroll 32 ambulatory study subjects with confirmed ECAC at the BIDMC, and each study subject will be monitored for up to 3 months.

Read the detailed description

Basal 6MWT performed as a standard of care in these patients will be compared to intervention ones to see if there is an improvement of at least 24 meters in their 6MWT distance, then both groups will be compared to see if there is a statistically significant difference between groups. Subjects, treating physicians and the research fellow performing the 6MWT will be blinded to the intervention; the only un-blinded personnel to the intervention will be the study coordinator who will be in charge of setting the CPAP before every intervention.

As part of the standard of care of our institution, patients that are referred due to suspicion of ECAC undergo initial PFTs, 6MWT and dynamic CT scan. With this information, patients are evaluated in clinic by the interventional pulmonary and thoracic surgery team who decide if the patient has the mentioned disease based on the previous testing. To corroborate the findings patients with moderate so severe disease are taken into a bronchoscopy with dynamic maneuvers as part of the standard of care. Initial bronchoscopic examination will be performed as described in the following section "I-Dynamic Bronchoscopy Protocol" as part of the standard of care of patients. After initial evaluation, during the same intervention, all patients that agree to participate in our study will go through a CPAP calibration procedure; in order to determine the adequate pressure to achieve airway patency of at least 70% during end exhalation in each individual case. After regular bronchoscopic examination, a full face F\&P SimplusTM CPAP mask (Fisher \& Paykel, Irvine, CA, USA) will be placed in all patients to prevent un-blinding the treating physician. The mask will be connected to a dual axis swivel adapter (T-adapter) and the bronchoscope will be advanced to the nares through the swivel adaptor; air leak will be prevented by the tight disposable cap of the swivel adaptor as described by Murgu et al.20

The calibration process will be performed following the technique first described by Ferguson et al10, bronchoscope will be positioned to assess the area with ECAC previously identified during regular examination; bronchoscope will be placed in the center of the lumen while assuring a constant 1-cm distance between the tip of the bronchoscope and the target area being measured, images will be taken during end inspiration and end expiration, gradual increases of 1 cmH2O in the CPAP pressure will be made until a 70% or less collapse is seen during end expiration by the bronchoscopist. At any given pressure increase the assessment of airway collapse will be made in 3 different respiratory cycles, the whole procedure will be recorded and posteriorly analyzed using morphometric bronchoscopy (Image J analysis program) as described in the "Morphometric Bronchoscopy" section.

Patient Population Subjects (>18 years of age) with previous diagnosis of ECAC confirmed by dynamic CT scan and/or bronchoscopy, who are currently receiving adequate medical therapy (Optimal medication doses and interventions defined by Interventional Pulmonary team) for comorbidities such as COPD, GERD, asthma, etc and are able to perform a 6 MWT.

Tracheobronchomalacia Evaluation CT Central Airway Protocol: All patients will be imaged according to our standard low dose CT central airway protocol21, which includes imaging during end-inspiratory and continuous dynamic expiratory phases. A multidetector row, helical CT scanner (LightSpeed; GE Medical Systems; Milwaukee, WI; or Aquilion; Toshiba America Medical Systems; Tustin, CA) which includes 4, 8, 16, and 64 detector-row systems will be used. Helical scanning will be performed in the cranio-caudal dimension during both respiratory phases. An experienced thoracic radiologist will review the CT images on a picture archiving and communication system (PACS) [Path-Speed, General Electric Medical Systems]. Using a computerized tracing tool in our PACS system, the inner wall of the airway will be hand traced at the level of maximal collapse in dynamic expiratory images to calculate the cross-sectional area of the airway (mm2). At the same level on end-inspiration images, the cross-sectional area of the airway lumen will be determined by using the same method. The percentage of luminal collapse between both respiratory phases will be calculated using the following formula= [1 - (Aee/Aei)],) X100, where Aee is luminal area at end expiration and Aei is luminal area at end inspiration. Mild ECAC is diagnosed if the percent of luminal collapse during dynamic expiration is 70-80%, moderate from 80-90% and severe >90%.

I-Dynamic Bronchoscopy Protocol All patients who are enrolled for the study will undergo bronchoscopy under minimal sedation using intravenous midazolam and fentanyl to allow spontaneous respiration. Lidocaine (1%, 20 ml), will be delivered by atomizer to the posterior oropharynx until the gag reflex is suppressed. The larynx, vocal cords, aryepiglottic folds and entire tracheobronchial tree will be irrigated with 1% lidocaine in 2-ml aliquots delivered through the bronchoscope during the procedure. An Olympus BF P180 video bronchoscope (Olympus America, Melville, NY) with a 4.9-mm outer diameter and 2.0-mm working channel will be used to minimize any stenting effect. The bronchoscope will be introduced into the proximal trachea at the level of the cricoid. At that point, patients will be instructed to take a deep breath, hold it and then blow it out (forced expiratory maneuver). Maneuver will be done at the following six sites: proximal trachea at the level of the cricoid; mid-trachea 5 cm proximal to the carina; distal trachea 2 cm proximal to the carina; right main stem bronchus at the right tracheobronchial angle; bronchus intermedius and left main bronchus at the left tracheobronchial angle. The maneuver will be repeated three times to ensure maximal airway narrowing during exhalation. All bronchoscopies will be video recorded and reviewed after the procedure to assess the degree of airway collapse. Mild ECAC is defined as a collapse 70-80%, moderate 80-90% and severe >90% of the airway during exhalation. This is standard of care for patients with EDAC.

After collapse degree is assessed trough forced expiratory maneuver, a nasal CPAP device (Define model) will be used in the patient, forced expiratory maneuvers will be repeated with different CPAP configurations until a 70% or less airway collapse is achieved. Calibration at which 70% airway collapse is achieved will be recorded and posteriorly used as the CPAP volume for the second 6MWT.

Morphometric bronchoscopy Cross-sectional area (CSA) of the airway will be calculated after the procedure by using the Image J analysis program (available free of charge at http://rsb.info.nih.gov/ij/) using two different measurement techniques as it was described by Murgu et al.22 The graphical measurement method uses color levels within the image to identify an appropriate region to be measured. Images are imported into Image J and a color balance window is opened (Image > Adjust > Color Balance). The histogram is then set to RGB color. The minimum and maximum bars are adjusted so that the resulting line corresponds to the highest point of the histogram. Only red, yellow, white, and black colors then remain. The black area, which represents the region to be measured for CSA, is selected using a wand tool. Using the region of interest (ROI) Manager (Analyze > Tools > ROI Manager) the selected area is then calculated in pixels. The manual measurement method requires that the operator selects the area to be measured by first opening the image using Image J. Using the polygon selections tool, the area of interest is then selected, and the ROI manager is used as in the graphical method.

Finally to provide an objective measurement in our patients, a collapsibility index (CI) will be calculated: difference in airway lumen size between end inspiration and end expiration: CI = (CSAinspir - CSAexpir)/(CSAinspire x 100%). Then measurements obtained for each patient during 3 respiratory cycles will be compared to discard that there is any significant statistical difference between them.

Six Minute Walk Test The 6MWT is a test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. Testing will be performed by the study personnel in a controlled environment. Supplies such as oxygen, sublingual nitroglycerine, aspirin, and albuterol (metered dose inhaler or nebulizer) will be available. The distance walked will be reported in meters. Data from both groups will be compared in order to verify if CPAP has a positive impact on exercise capacity in these patients. Since subjects have never used CPAP before and are not used to the device a 10 minute Run-in period will be allowed in which the CPAP will be placed while the patient is seating to allow he/she to get used to the sensation generated by the machine, at this time the study personnel will also look for air leaks that could compromise the results of the study. Either a regular CPAP or a sham-CPAP will be used for the Run-in period depending on the result of the randomization; this will be done to avoid the patient noticing the difference between this period and the 6 MWT which could happen if only regular CPAP was used.

Sham-CPAP The Sham-CPAP will be created following the methods of Farre et al23 And Rodway et al.24 An enlarged air leak incorporated into the exhalation valve will be positioned between the mask and the CPAP tubing, allowing airflow resistance of the exhalation port to be almost eliminated by increasing its area, thereby virtually cancelling positive pressure. Also an orifice restrictor in the CPAP circuit will be connected between the CPAP unit and the tubing in order to load the blower with the same airflow resistance as in true CPAP. These changes allow the ventilator operating noise and the airflow through the exhalation port remain unchanged, which are crucial to a CPAP placebo.

Enrollment CPAP naïve patients with a diagnosis of ECAC will be informed about the trial and if interested will be recruited for our randomized controlled study. Patients who meet the inclusion criteria by the principle investigator or co-investigators will be approached during an office visit to our Chest Disease Clinic at BIDMC

Being tested
Continuous positive airway pressure (CPAP) device, Sham-continuous positive airway pressure (CPAP) device
Keywords
Continuous Positive Airway Pressure, Tracheobronchomalacia, Excessive Dynamic Airway Collapse, Excessive Central Airway Collapse
Medical subject headings
Tracheobronchomalacia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Continuous positive airway pressure (CPAP) deviceDevice

    Use of a CPAP during a 6 minute walk test to maintain the airways open during the respiratory cycle

  • Sham-continuous positive airway pressure (CPAP) deviceDevice

    An enlarged air leak incorporated into the exhalation valve will be positioned between the mask and the CPAP tubing, allowing airflow resistance of the exhalation port to be almost eliminated by increasing its area, thereby virtually cancelling positive pressure. Also an orifice restrictor in the CPAP circuit will be connected between the CPAP unit and the tubing in order to load the blower with the same airflow resistance as in true CPAP.

Study groups in NCT04217603
Study groupRoleWhat they receive
Group 1ExperimentalThis group will perform a 6MWT with CPAP
Receives: Device: Continuous positive airway pressure (CPAP) device
Group 2Sham comparatorThis group will perform a 6MWT with a sham-CPAP
Receives: Device: Sham-continuous positive airway pressure (CPAP) device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Difference in meters walked in 6MWTs

    Statistical difference between the 6 MWT results of the CPAP and sham-CPAP groups as compared with the initial results of the 6 MWT and between groups using ANCOVA.

    Measured: 3 months

Secondary outcomes (3)
  1. Modified Borg scale scores for dyspnea

    Measured: 3 months

  2. Modified Borg scale scores for exertion

    Measured: 3 months

  3. Subjective assestment of cough during 6MWTs

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jan 2020
  2. Study start1 Mar 2023
  3. Primary completion29 Sep 2026 (estimated)
  4. Study completion29 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This prospective, randomized placebo controlled, double-blind clinical trial will be conducted at Beth Israel Deaconess Medical Center (BIDMC) in accordance with Good Clinical Practice Standards and under IRB supervision. We plan to enroll a total of 32 patients with ECAC randomized by an opaque envelope technique into two different groups: group 1 (CPAP) and group 2 (sham-CPAP) * Group 1: This group will perform a 6MWT with CPAP * Group 2: This group will perform a 6MWT with a sham-CPAP
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
32 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04217603
Sponsor's protocol ID
2019P001034
Status last verified
Apr 2026
First submitted
2 Jan 2020
Last updated
13 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Publications

  • Leong P, Bardin PG, Lau KK. What's in a name? Expiratory tracheal narrowing in adults explained. Clin Radiol. 2013 Dec;68(12):1268-75. doi: 10.1016/j.crad.2013.06.017. Epub 2013 Aug 13.

    PubMed 23953005
  • Murgu S, Colt H. Tracheobronchomalacia and excessive dynamic airway collapse. Clin Chest Med. 2013 Sep;34(3):527-55. doi: 10.1016/j.ccm.2013.05.003. Epub 2013 Jun 27.

    PubMed 23993822
  • Ridge CA, O'donnell CR, Lee EY, Majid A, Boiselle PM. Tracheobronchomalacia: current concepts and controversies. J Thorac Imaging. 2011 Nov;26(4):278-89. doi: 10.1097/RTI.0b013e3182203342.

    PubMed 22009081
  • Park JG, Edell ES. Dynamic Airway Collapse: Distinct From Tracheomalacia. J Bronchol. 2005;12(3):143-146. doi:10.1097/01.laboratory.0000171764.65217.f8

  • Boiselle PM, O'Donnell CR, Bankier AA, Ernst A, Millet ME, Potemkin A, Loring SH. Tracheal collapsibility in healthy volunteers during forced expiration: assessment with multidetector CT. Radiology. 2009 Jul;252(1):255-62. doi: 10.1148/radiol.2521081958. Epub 2009 May 6.

    PubMed 19420322
  • Majid A, Fernandez L, Fernandez-Bussy S, Herth F, Ernst A. [Tracheobronchomalacia]. Arch Bronconeumol. 2010 Apr;46(4):196-202. doi: 10.1016/j.arbres.2009.10.011. Epub 2009 Dec 9. Spanish.

    PubMed 20004507
  • Cepeda S, Climent M, Martinez Moragon E. [Bronchomalacia in adults: an infrequent entity that improves with continuous positive pressure on the airway]. An Sist Sanit Navar. 2016 Dec 30;39(3):457-458. doi: 10.23938/ASSN.0230. No abstract available. Spanish.

    PubMed 28032884
  • Sala A, Martínez Deltoro A, Martínez Moragón E. Asmática con broncomalacia y buena respuesta al tratamiento con presión positiva continua en la vía aérea. Arch Bronconeumol. http://www.archbronconeumol.org/es/pdf/S030028961300272X/S300/.

  • Adliff M, Ngato D, Keshavjee S, Brenaman S, Granton JT. Treatment of diffuse tracheomalacia secondary to relapsing polychondritis with continuous positive airway pressure. Chest. 1997 Dec;112(6):1701-4. doi: 10.1378/chest.112.6.1701.

    PubMed 9404780
  • Ferguson GT, Benoist J. Nasal continuous positive airway pressure in the treatment of tracheobronchomalacia. Am Rev Respir Dis. 1993 Feb;147(2):457-61. doi: 10.1164/ajrccm/147.2.457.

    PubMed 8430971
  • Jiang AG, Gao XY, Lu HY. Diagnosis and management of an elderly patient with severe tracheomalacia: A case report and review of the literature. Exp Ther Med. 2013 Sep;6(3):765-768. doi: 10.3892/etm.2013.1195. Epub 2013 Jul 2.

    PubMed 24137262
  • Kandaswamy C, Balasubramanian V. Review of adult tracheomalacia and its relationship with chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2009 Mar;15(2):113-9. doi: 10.1097/MCP.0b013e328321832d.

    PubMed 19532025
  • Carden KA, Boiselle PM, Waltz DA, Ernst A. Tracheomalacia and tracheobronchomalacia in children and adults: an in-depth review. Chest. 2005 Mar;127(3):984-1005. doi: 10.1378/chest.127.3.984.

    PubMed 15764786
  • Murgu SD, Colt HG. Treatment of adult tracheobronchomalacia and excessive dynamic airway collapse : an update. Treat Respir Med. 2006;5(2):103-15. doi: 10.2165/00151829-200605020-00004.

    PubMed 16512691
  • Murgu SD. Pneumatic stenting for tracheobronchomalacia. J Bronchology Interv Pulmonol. 2014 Apr;21(2):109-12. doi: 10.1097/LBR.0000000000000053. No abstract available.

    PubMed 24739682

Questions about this trial

What is this clinical trial studying?

A study testing Continuous positive airway pressure (CPAP) device in people with Tracheobronchomalacia and Excessive Dynamic Airway Collapse, run by Beth Israel Deaconess Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Difference in meters walked in 6MWTs (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04217603, which also lists 25 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in